These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


319 related items for PubMed ID: 23461155

  • 1. Change in ocular refraction after tropicamide cycloplegia in preschool children.
    Nawrot P, Przekoracka-Krawczyk A, Perz K, Rusiak P, Naskrecki R.
    Klin Oczna; 2012; 114(4):278-81. PubMed ID: 23461155
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Accomodative tone in children under general anesthesia.
    Salchow DJ, Marcus I, Golembeski TJ, Wang X, Li F.
    Am J Ophthalmol; 2013 Nov; 156(5):1034-1039.e2. PubMed ID: 23972304
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cyclopentolate versus tropicamide cycloplegia: A systematic review and meta-analysis.
    Yazdani N, Sadeghi R, Momeni-Moghaddam H, Zarifmahmoudi L, Ehsaei A.
    J Optom; 2018 Nov; 11(3):135-143. PubMed ID: 29132914
    [Abstract] [Full Text] [Related]

  • 5. Comparison of tropicamide and cyclopentolate for cycloplegic refractions in myopic adult refractive surgery patients.
    Hofmeister EM, Kaupp SE, Schallhorn SC.
    J Cataract Refract Surg; 2005 Apr; 31(4):694-700. PubMed ID: 15899444
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cycloplegia in African-American children.
    Kleinstein RN, Mutti DO, Manny RE, Shin JA, Zadnik K.
    Optom Vis Sci; 1999 Feb; 76(2):102-7. PubMed ID: 10082056
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tropicamide (1%): an effective cycloplegic agent for myopic children.
    Manny RE, Hussein M, Scheiman M, Kurtz D, Niemann K, Zinzer K, COMET Study Group.
    Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1728-35. PubMed ID: 11431435
    [Abstract] [Full Text] [Related]

  • 10. Influences of cycloplegia with topical atropine on ocular higher-order aberrations.
    Hiraoka T, Miyata K, Nakamura Y, Miyai T, Ogata M, Okamoto F, Oshika T.
    Ophthalmology; 2013 Jan; 120(1):8-13. PubMed ID: 23084238
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Short-term refractive change and ocular parameter changes after cycloplegia.
    Cheng HC, Hsieh YT.
    Optom Vis Sci; 2014 Sep; 91(9):1113-7. PubMed ID: 25036542
    [Abstract] [Full Text] [Related]

  • 13. Tropicamide Versus Cyclopentolate for Cycloplegic Refraction in Pediatric Patients With Brown Irides: A Randomized Clinical Trial.
    Al-Thawabieh W, Al-Omari R, Abu-Hassan DW, Abuawwad MT, Al-Awadhi A, Abu Serhan H.
    Am J Ophthalmol; 2024 Jan; 257():218-226. PubMed ID: 37797867
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of the Shin-Nippon SRW-5000 autorefractor in children.
    Chat SW, Edwards MH.
    Ophthalmic Physiol Opt; 2001 Mar; 21(2):87-100. PubMed ID: 11261351
    [Abstract] [Full Text] [Related]

  • 15. Cycloplegic refraction is the gold standard for epidemiological studies.
    Morgan IG, Iribarren R, Fotouhi A, Grzybowski A.
    Acta Ophthalmol; 2015 Sep; 93(6):581-5. PubMed ID: 25597549
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of cycloplegic agents: results of a randomized controlled trial in nigerian children.
    Ebri A, Kuper H, Wedner S.
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1025-31. PubMed ID: 17325142
    [Abstract] [Full Text] [Related]

  • 20. The cycloplegic effects of cyclopentolate and tropicamide on myopic children.
    Lin LL, Shih YF, Hsiao CH, Su TC, Chen CJ, Hung PT.
    J Ocul Pharmacol Ther; 1998 Aug; 14(4):331-5. PubMed ID: 9715436
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.